Acadia Now Has The Cash To Finish Phase III On Its Own
This article was originally published in The Pink Sheet Daily
Executive Summary
After announcing promising Phase III data in late November, Acadia Pharmaceuticals conducted a private placement of nearly 20 million shares that will net the company $86.4 million in funds to continue running its Phase III program for pimavanserin in Parkinson’s disease psychosis.